Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Testosterone Gel 1% in Post-menopausal Women
NCT02667561Phase 1Withdrawn
- Sponsor
- Biolab Farmacêutica
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of Testosterone TEPI patch in hypoactive sexual desire disorder (HSDD) (4 arms), sponsored by Biolab Farmacêutica. Primary endpoints: Area Under the Curve at 28 days, Maximum Concentration at 28 days and 2 more. Planned start Jul 2017; status: withdrawn.
02
Drugs
Testosterone TEPI patch
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT02667561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667561.